Los mejores médicos para el tratamiento de Sarcoma de Ewing en el extranjero — Página 2

El Dr. Mahmoud M. El Zembely es hemato-oncólogo pediatra. Trata la leucemia linfoblástica aguda, la leucemia mieloide aguda y la leucemia mieloide crónica. Atiende linfomas de Hodgkin y no Hodgkin, nefroblastoma (tumor de Wilms), neuroblastoma y tumores óseos y hepáticos. Su labor incluye tumores de células germinales gonadales y extragonadales, rabdomiosarcoma y sarcomas de partes blandas no rabdomiosarcomatosos. También atiende cánceres raros y proporciona atención al superviviente oncológico.

Acreditaciones: M.B.B.Ch, Universidad de Assiut, 2006. Máster en Oncología Pediátrica y Hematología Maligna, 2011. Fellowship clínico en trasplante de médula ósea pediátrico, Seattle Cancer Care Alliance, 2015–2017. Doctorado, 2020.

Cargos: South Egypt Cancer Institute–Universidad de Assiut: Oncología Pediátrica, 2008–2012. Profesor asistente, 2012–2019. Profesor, 2020–2024. Shefa Al‑Orman Cancer Center, Lúxor: Jefe de Oncología Pediátrica, 2020–presente.

El profesor Raanan Berger, MD, PhD, es oncólogo médico y radioterapeuta. Es director del Centro Oncológico del Sheba Medical Center y dirige su unidad de investigación clínica. Fue incluido en la lista “Best Doctors” de Forbes Israel (2025). Lidera el programa de oncología genitourinaria, con enfoque en el cáncer de próstata. Su práctica incluye terapia sistémica y radioterapia en un modelo multidisciplinario centrado en el paciente.

Es especialista en oncología. Obtuvo los títulos de MD y PhD en la Universidad de Tel Aviv y completó su formación clínica en Sheba. Posteriormente realizó una beca posdoctoral en Dana-Farber/Harvard, centrada en cáncer de próstata con el Dr. Philip Kantoff y en oncología molecular en el laboratorio del Dr. William C. Hahn. Es miembro de ESMO y ASCO. Es coautor de más de 20 artículos revisados por pares, entre ellos estudios sobre resultados en cáncer de próstata de alto frente a muy alto riesgo y sobre BRCA1/2 en grandes cohortes.

La Dra. Iris Kventsel, MD, es hemato-oncóloga pediatra y especialista en trasplante de médula ósea (TMO) en el Centro Médico Sheba. Es médica adjunta en la División de Hemato-Oncología Pediátrica y TMO del Hospital Infantil Edmond y Lily Safra. Su enfoque clínico son los sarcomas pediátricos, incluidos el sarcoma de Ewing, el osteosarcoma y el rabdomiosarcoma.

Brinda atención multidisciplinaria que incluye trasplante y terapias celulares. También utiliza protocolos de quimioterapia actuales y terapias dirigidas para cánceres infantiles complejos.

Su investigación se centra en la predisposición genética al cáncer, incluido el síndrome de Li-Fraumeni, y en genes de susceptibilidad al cáncer. Ha publicado en oncología pediátrica, biología de células madre y oncología quirúrgica (HIPEC). Forma parte del personal académico de la Universidad de Tel Aviv. Formación: MD, Technion; residencia en Pediatría, Assaf HaRofeh; subespecialidad en Hemato-Oncología Pediátrica, Sheba.

El Dr. Netanel Meushar dirige el departamento de oncología ósea en el Centro Médico Rambam.

• Especializado en el tratamiento del cáncer de hueso
• Con experiencia en el manejo de casos complejos de sarcoma
• Trabaja en un centro médico líder en Israel

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

La Prof. Myriam Ben Arush es una especialista reconocida internacionalmente en Oncología Pediátrica y Trasplante de Médula Ósea, y dirige la División Pediátrica en el Hospital Infantil Ruth Rappaport.

• Galardonada con el Premio del Ministerio de Salud por su destacada labor
• Distinguida con la Legión de Honor en Francia
• Nombrada una de las doctoras más dedicadas del mundo por la Asociación Médica Mundial
• Miembro del Grupo de Oncología Pediátrica de EE. UU. y de sociedades oncológicas europeas

El Prof. Onder Ofluoglu cuenta con de experiencia médica, con una formación de especialización altamente cualificada en tumores óseos y de tejidos blandos en la Universidad de Pensilvania y la Universidad de California.

• Especializado exclusivamente en cirugía oncológica ortopédica
• Formado en cirugía de Ilizarov en el Centro Científico Ilizarov en Rusia
• Autor o coautor de más de 50 documentos científicos
• Miembro de la Sociedad de Oncología de Tejidos Conectivos y de sociedades europeas de ortopedia

Con más de _doctor_9338_años_ de experiencia en hematología y oncología pediátrica, el Prof. Dogru se especializa en cánceres infantiles complejos en el Hospital Universitario Biruni.

• Formación especializada en oncología pediátrica en la Universidad de Estambul
• Experiencia en trasplante de médula ósea
• Miembro de la Organización Europea de Trasplante de Médula Ósea
• Cargos de profesor asistente en varias universidades prestigiosas

El Dr. Apak se especializa en hematología y oncología pediátrica, con una amplia experiencia en trasplante de médula ósea y terapia de células CAR-T en el Hospital Universitario Biruni.

• Más de _doctor_6792_años_ dirigiendo la División de Hematología-Oncología Pediátrica en la Universidad de Estambul-Cerrahpaşa
• Publicó 75 artículos internacionales sobre tratamientos de oncología pediátrica
• Editor asistente de la revista Turkish Pediatrics Archives
• Miembro de la junta de la Sociedad Pediátrica Turca y la Asociación Turca de Medicina del Adolescente

• Se especializa en el tratamiento del sarcoma de Ewing con quimioterapia, cirugía y radiación.
• Experiencia en técnicas quirúrgicas para preservar las extremidades y preservar la función y la apariencia.
• Formado internacionalmente en Alemania, Estados Unidos y Australia.
• Aclamado por un enfoque multidisciplinario de casos complejos de sarcoma.
• Certificado por la Junta en Cirugía Ortopédica para la práctica clínica avanzada.
• Miembro de la Sociedad Internacional de Cirugía Ortopédica y Traumatología (SICOT).
• Ofrece consultas en línea para pacientes globales con sarcoma de Ewing.
• Consulta en inglés y alemán, asegurando una comunicación clara.

La Prof. Dra. Suna Emir se graduó en la Facultad de Medicina de la Universidad de Hacettepe en 1989. Realizó la residencia en pediatría en la Universidad de Hacettepe entre 1990 y 1995. En 2001 completó la subespecialidad en oncología pediátrica en el Instituto de Oncología de la Universidad de Hacettepe. En 2004 obtuvo el título de Profesora Asociada. De 2004 a 2009 trabajó en el Hospital de Formación e Investigación en Salud y Enfermedades Infantiles Dışkapı de Ankara, donde fundó la Clínica de Oncología Pediátrica. En 2009 se desempeñó como Subjefa de Oncología Pediátrica. De 2009 a 2016 fue responsable de formación en hematología–oncología pediátrica en el Hospital de Formación e Investigación en Hematología–Oncología y Salud y Enfermedades Infantiles de Ankara. Desde 2019 es Profesora y docente fundadora en Salud y Enfermedades Infantiles en la Universidad Atilim.

Es experta en pediatría general y hematología–oncología pediátrica. Participa activamente en la formación de residentes y subespecialistas. Sus intereses clínicos incluyen las enfermedades de la infancia desde el nacimiento hasta los 18 años, el linfoma, los tumores sólidos, el trasplante autólogo de médula ósea, la anemia, los trastornos hemorrágicos, las enfermedades hematológicas hereditarias, los hemangiomas y otros tumores benignos, y las adenopatías.

Jefa del Centro de Oncología de Charité – La Dra. Keilholz aporta una experiencia de primer nivel en casos complejos de cáncer.

• Especializada en oncología con enfoque en el sarcoma de Ewing
• Dirige uno de los principales centros oncológicos de Berlín

Más de _doctor_3339_años_ de especialización en oncología pediátrica – La Dra. López-Ibor dirige la Unidad de Hematología y Oncología Pediátrica en HM Montepríncipe.

• Experta en el tratamiento de tumores óseos como el sarcoma de Ewing
• Formada en la Universidad de Maryland, un centro líder en oncología pediátrica en EE. UU.
• Exjefa de oncología pediátrica en el Hospital Universitario Clínica San Rafael
• Autora de numerosas publicaciones en revistas nacionales e internacionales

Angelika Eggert es jefa del Departamento de Oncología Pediátrica en Charité, uno de los hospitales universitarios más grandes de Europa.

• Dirige un departamento importante en un hospital europeo de primer nivel
• Se centra exclusivamente en el tratamiento del cáncer infantil
• Acceso a los últimos ensayos clínicos para pacientes jóvenes

El Dr. Kharya, hematólogo-oncólogo pediátrico, se especializa en trasplantes de médula ósea para cánceres infantiles en Artemis Hospitals.

• Experiencia en hematología y oncología pediátrica
• Especializado en trasplante de médula ósea
• Enfocado en el tratamiento de cánceres infantiles

El profesor Demirkaya se especializa en oncología pediátrica con 27 años de enfoque en el sarcoma de Ewing en el Hospital Medicana Bursa.

• Formado en el programa de residencia de oncología pediátrica de la Universidad Bursa Uludag
• Ex miembro de la facultad de la Facultad de Medicina de la Universidad Bursa Uludag
• Trabajó en el Centro de Hematología, Oncología y Trasplante de Médula Ósea Pediátrica GATA
• Actual profesor de oncología pediátrica en Medicana Bursa

La Dra. Shruti Kate se especializa en el sarcoma de Ewing con experiencia en inmunoterapia y terapia metronómica para cánceres avanzados. Se formó en el Tata Memorial Hospital, un centro oncológico líder.

• Doctorado en Oncología Médica por el Tata Memorial Hospital
• Miembro de ASCO, ESMO y otras prestigiosas sociedades oncológicas
• Presentó investigaciones sobre cáncer de pulmón en el WCLC 2018
• Experiencia en el tratamiento de tumores pediátricos y tumores sólidos

La Dra. Blanca Lopez Ibor dirige la Unidad de Hematología y Oncología Pediátrica en HM Hospitales, con más de 31 años de experiencia en oncología pediátrica.

• Especializada en trastornos hematológicos y oncológicos en niños y adolescentes
• Consultora de la OMS y la UNESCO en oncología pediátrica
• Presidenta de la Fundación Jaime Alonso Abruña, que ayuda a niños con problemas de salud graves
• Miembro de la Sociedad Internacional de Oncología Pediátrica (SIOP)
• Profesora en la Universidad Complutense de Madrid y la Universidad CEU San Pablo